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Abstract. Bofutsushosan, a herbal (traditional Kampo) medi-
cine, is administered to obese patients in North-East Asia. 
Bofutsushosan has been reported to exert various anti-obesity 
effects by stimulating the adipose tissue. The present study 
describes the case of a patient who developed a severe pulmo-
nary injury that was potentially associated with bofutsushosan 
therapy. A 52-year-old woman was admitted to Mito Medical 
Center, University of Tsukuba, Mito Kyodo General Hospital 
(Mito, Japan) due to progressive dyspnea. Two months 
previously, bofutsushosan had been newly prescribed for 
her obesity. Bilateral ground-glass opacities and progressive 
respiratory deterioration suggested respiratory failure due to 
a therapeutic agent-induced lung injury. With discontinuation 
of bofutsushosan and the administration of a corticosteroid, 
an improvement in her respiratory condition was achieved, 
although sequelae remained in certain areas of the lungs. 
Resumption of other therapeutic agents did not reinduce the 
lung injury. Therefore, a diagnosis of bofutsushosan-induced 
lung injury was made. Although bofutsushosan-induced lung 
injury is particularly rare, clinicians should consider it when 
bofutsushosan is used.
Introduction
Bofutsushosan (Tsumura Co., Tokyo, Japan), one of the tradi-
tional herbal medicines, which was developed by Liu Wansu 
(a well-known physician of traditional Chinese medicine in the 
12th century), is known as an effective medication for obesity 
in North-East Asia. Many Kampo practitioners are aware of 
bofutsushosan and its effects on obesity, which have previ-
ously been reported in the Japanese literature (1-3). However, 
to the best of our knowledge, this has not been reported in the 
English literature. The aim of the present study is to introduce 
this traditional herbal medicine in areas outside of North-East 
Asia, for the ‘non-Kampo’ clinicians. Thus, the present study 
describes the case of a patient who was successfully treated 
following the development of a pulmonary injury that may 
have been associated with bofutsushosan therapy.
Case report
A 52-year-old woman was admitted to Mito Medical Center, 
University of Tsukuba, Mito Kyodo General Hospital (Mito, 
Japan) in October, 2011 for diffuse ground-glass opacity 
(GGO) in each lung, which was noted on a chest X-ray. The 
patient was orally administered 7.5 g/day bofutsushosan to 
treat her obesity. Two months after initiation of bofutsushosan 
administration, the patient developed shortness of breath and 
was dyspneic at rest. On admission, the respiratory rate was 
22 breaths/min and a decreased oxygen saturation of 93% 
was observed. A chest examination revealed inspiratory fine 
crackles in the base of each lung. The heart sounds were 
normal, the jugular vein was not dilated, and hepatomegaly 
and peripheral edema were absent. Upon admission, an 
arterial blood gas analysis on 10-liter oxygen indicated 
the following: pH 7.506; PO2, 65.3 torr; PCO2, 24.5 torr; 
HCO3-, 18.9 mEq/l; Na, 136 mEq/l; and Cl, 100 mEq/l. The 
blood chemistry was significant for the level of C‑reactive 
protein (25.17 mg/dl) and KL-6 (2,370 U/ml). No elevation 
in antibody titers of Mycoplasma, Legionella pneumophila, 
and Chlamydia psittaci was observed. Antinuclear 
antibody testing, and serum perinuclear antinuclear 
cytoplasmic antibody, anti-cyclic citrullinated peptide 
antibody, and Cryptococcus and Aspergillus antigen testing 
were all negative. An electrocardiogram demonstrated 
a normal sinus rhythm with nonspecific ST-T changes. 
An echocardiographic assessment showed that the left 
ventricular ejection fraction and wall motion were normal. 
A chest radiograph taken on admission detected bilateral 
GGOs with consolidation (Fig. 1). Additionally, a chest 
computed tomography (CT) scan showed bilateral GGOs 
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with consolidation (Fig. 2). Blood, sputum and urine cultures 
did not indicate any bacterial infections. A bronchoalveolar 
lavage obtained from the left upper lobe demonstrated a total 
cell count of 6.4x105/ml with 53.0% lymphocytes. Despite 
the administration of oxygen therapy and a broad-spectrum 
intravenous antibiotic, levofloxacin, the patient's respiratory 
condition progressively deteriorated within a few hours of 
admission. Considering the possibility of medication-induced 
lung injury, all medications were withdrawn, including 
bofutsushosan. Due to the rapid deterioration of the 
patient, methylprednisolone pulse therapy (1,000 mg/day 
for 3 days) was initiated. The respiratory condition of the 
patient improved in response to the pulse therapy and the 
chest CT scan, which was performed 2 weeks after initiation 
of steroid therapy, showed that the GGOs in each lung had 
disappeared, although dense consolidations remained in 
certain areas of the lungs (Figs. 3 and 4). The patient was 
discharged without oxygen inhalation. Maintenance steroid 
therapy using prednisolone was tapered off within 3 weeks, 
and a relapse requiring oxygen therapy did not occur. The 
patient's respiratory condition remained stable 1 year after 
this occurrence of acute respiratory failure.
Discussion
Bofutsushosan, a herbal (traditional Kampo) medicine, is 
administered to treat obese patients in North-East Asia. 
Bofutsushosan was reported to exert various anti-obesity 
effects by stimulating the adipose tissue in rodents (4,5). 
Azushima et al recently reported that bofutsushosan exerted 
a favorable effect on metabolism, including an antihyperten-
sive effect, via its beneficial effect on adipose tissue function, 
as well as its appetite inhibitory effect in a mouse model of 
human metabolic disorders with obesity (6). The present study 
describes the case of a patient who was successfully treated 
for a pulmonary injury that was potentially associated with 
bofutsushosan therapy.
Numerous types of therapeutic agent cause lung injury (7,8); 
however, the incidence varies for each individual therapeutic 
agent. Typically, therapeutic agent-induced lung injury occurs 
with acute (day to weeks) or subacute (months) presentation. 
Symptoms, such as dyspnea on exertion and a non-productive 
cough, as well as specific markers, such as KL‑6, are generally 
unremarkable. Although the most common abnormality 
observed by chest CT is GGOs with or without consolidation, 
Figure 1. Chest radiograph performed on admission detected bilateral 
ground-glass opacities in each lung.
Figure 2. Chest computed tomography scan at the time of admission exhib-
ited bilateral ground-glass opacities.
Figure 3. Chest radiograph 2 weeks after the initiation of steroid therapy 
demonstrated the absence of the ground-glass opacities in each lung.
Figure 4. Chest computed tomography scan 2 weeks after the initiation of 
steroid therapy demonstrated the absence of the ground-glass opacities in 
each lung.
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although chest radiography and chest CT findings are 
unremarkable. There are no universal diagnostic criteria for 
therapeutic agent-induced lung injury. Therefore, the diagnosis 
of therapeutic agent-induced lung injury generally depends on 
a definite temporal association between an exposure to the 
causative agent and the development of respiratory symptoms. 
The most important factor for an accurate diagnosis is the 
exclusion of all other possible explanations for the cause of the 
lung injury (8).
In the present study, heart failure and pulmonary infection 
were ruled out to establish a final diagnosis of bofutsush-
osan-induced lung injury. As mentioned above, no signs of 
suspected congestive heart failure, such as jugular venous 
distention, edema, and extra heart sounds were identified. The 
echocardiographic assessment showed that the left ventricular 
ejection fraction and wall motion were normal. Diuretics, a 
β-blocker, an angiotensin-converting enzyme inhibitor and 
Digitalis were not required for the treatment of this patient. 
Therefore, this episode was determined to be unrelated to heart 
failure. Additionally, respiratory infection was excluded from 
the differential diagnosis, as the broad-spectrum antibiotics 
were invalid. The patient in the present study had been taking 
bofutsushosan for 2 months prior to the development of her 
symptoms. The dyspnea had rapidly worsened since that time, 
but improved following the discontinuation of bofutsushosan 
and the initiation of steroid therapy. Certain cases of therapeutic 
agent-induced interstitial lung injury demonstrated sequelae of 
fibrosis, consolidation and organization (9,10). However, with 
considerable resolution of the GGOs, an improvement of the 
respiratory condition of the current patient was achieved.
Thus, the present study describes a case of lung injury 
associated with bofutsushosan in a patient. To the best 
of our knowledge, this is the first case report showing 
bofutsushosan-induced lung injury in English literature. 
Diffuse GGOs were present throughout each of the lungs, 
which is a common finding in therapeutic agent-induced 
lung injury (11). Bofutsushosan is becoming an increasingly 
prescribed medication for obesity control. Although the 
underlying mechanism by which bofutsushosan induces 
lung injury remains unclear, clinicians must be aware of the 
possibility of this condition to prevent further morbidity and 
mortality in obese patients.
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